Evidence map›Paper›PMID 28543687›Full record

ArticleBritish journal of clinical pharmacology2017

Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study.

Cristiana Cipriani, Jessica Pepe, Carolina Clementelli, Rizieri Manai, Luciano Colangelo, Valeria Fassino, Luciano Nieddu, Salvatore Minisola

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04303026 (A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04303026 phase3unknown statusnot on this mapstarted 2020, after this paper: background citation

A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis

TypeinterventionalSponsorVestre Viken Hospital TrustRan2020 to 2024Enrolled70ConditionsOsteoarthritis, HipArmsZoledronic Acid, Saline 0.9%
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Normocalcemic primary hyperparathyroidism.Archives of endocrinology and metabolism · 2022
    Review
  4. Article
  5. Article
  6. Bisphosphonate nephropathy: A case series and review of the literature.British journal of clinical pharmacology · 2021
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Cristiana CiprianiDepartment of Internal Medicine and Medical Disciplines, 'Sapienza' University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Jessica PepeDepartment of Internal Medicine and Medical Disciplines, 'Sapienza' University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Carolina ClementelliDepartment of Internal Medicine and Medical Disciplines, 'Sapienza' University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Rizieri ManaiDepartment of Internal Medicine and Medical Disciplines, 'Sapienza' University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Luciano ColangeloDepartment of Internal Medicine and Medical Disciplines, 'Sapienza' University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Valeria FassinoDepartment of Internal Medicine and Medical Disciplines, 'Sapienza' University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Luciano NiedduFaculty of Economics, UNINT University, Via Cristoforo Colombo 200, 00147, Rome, Italy.
Salvatore MinisolaDepartment of Internal Medicine and Medical Disciplines, 'Sapienza' University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Sapienza University of Rome · ITPoliclinico Umberto I · ITUniversità degli Studi Internazionali di Roma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe pilot study was designed to evaluate the early effect of intravenous (i.v.) zoledronic acid (ZA) on renal function.

methodsFive mg i.v. ZA was administered to 23 patients with osteoporosis (17 women and 6 men, mean age 73 ± 7 SD years). Urinary NGAL, KIM-1, and MCP-1, plasma (p) MCP-1 and serum (s) IL-18, serum calcium (sCa), Creatinine clearance (CrCl), parathyroid hormone (PTH), plasma C-terminal FGF23 (pFGF23), serum (s) Klotho, calcium excretion (CaEx) and renal threshold phosphate concentration/GFR (TmPO

resultsThere was a significant decrease in sCa and CaEx at 24 h (-4.1 ± 2.8%, P < 0.01 and -28 ± 59%, P < 0.05, respectively) and Day 30 (-3.9 ± 4%, P < 0.001 and -26 ± 43%, P < 0.01) and a significant increase in PTH (79.8 ± 95.8%) at Day 30 (P < 0.001) compared to baseline. TmPO

conclusionsOur pilot study suggests that there is no direct acute effect of ZA on kidney function. The increase in plasma MCP-1 and serum IL-18 concentration could be associated with the stimulation of immunity mechanisms occurring soon after the administration of the drug. Secondary hyperparathyroidism develops shortly after the infusion of ZA and is maintained even after 1 month.

Indexed as

Acute Kidney InjuryAgedAged, 80 and overBiomarkersBone Density Conservation AgentsCalciumChemokine CCL2DiphosphonatesFemaleFibroblast Growth Factor-23HumansHyperparathyroidism, SecondaryImidazolesInfusions, IntravenousInterleukin-18MaleBiomarkersBone Density Conservation AgentsCalciumCCL2 protein, humanChemokine CCL2DiphosphonatesFGF23 protein, humanFibroblast Growth Factor-23IL18 protein, humanImidazolesInterleukin-18Zoledronic Acidacute kidney injuryosteoporosisrenal failurezoledronic acid

Identifiers

PMID28543687
PMCPMC5595932
OpenAlexW2617490804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.